trending Market Intelligence /marketintelligence/en/news-insights/trending/_HhynyUI7bHayiF4HEuC6Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

J&J seeks EU approval for Spravato in depression with suicidal intent

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

J&J seeks EU approval for Spravato in depression with suicidal intent

Johnson & Johnson filed an application with the European Medicines Agency for approval of its esketamine nasal spray Spravato to treat adults with major depressive disorder who have active suicidal ideation with intent.

The nasal spray is already approved in the U.S. and Europe as a medication for adults with treatment-resistant depression.

J&J unit Janssen Pharmaceuticals Inc.'s application is backed by data from two late-stage clinical studies named Aspire I and Aspire II. Results from the studies showed Spravato to be superior in decreasing depressive symptoms versus placebo.

The company filed an application with the U.S. Food and Drug Administration in October 2019 seeking expanded approval for Spravato to treat depression with suicidal intent. The drug won the FDA's breakthrough-therapy designation in August 2019 for this use.